In The Cancer Genome Atlas (TCGA) dataset that includes 32 distinct studies and over 10,000 cancer cases, the prevalence of TP53 mutations are 15.20%, deletions 15.90%, and biallelic inactivation events are 22.02% of cases [17]. The gene discussed is TP53; the disease is cancer.